Pharma 2020: Marketing the future – Which path will you take? #idm #pharma

Posted On Dec 25 2017 by

#pharmaceutical marketing companies # Pharma 2020: Marketing the future Which path will you take? By 2020 the current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model as the industry shifts from a mass-market to a target-market approach to increase revenue. Pharma 2020: Marketing the future – Which path will you take? the third in the Pharma 2020 series, outlines a confluence of dynamics that lead to a new marketing and sales system with a smaller, more agile and smarter sales force. The pharma industry is no longer being rewarded for incremental innovation, …


Download vision to decision report: Pharma 2020: PwC #pharmaceutical #information

Posted On Dec 20 2017 by

#pharmaceutical industry trends # Download the report In this report, we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter. The pharmaceutical industry is at a critical juncture. The tools to develop remarkable new medicines are materialising, demand for its products is increasing and the barriers to free trade are falling. But pharma also faces major economic and operational challenges, if it’s to capitalise on these opportunities and create more value for healthcare payers, providers and patients. Many of the conditions that will determine what happens in 2020 are already in place. …


Changes in pharma supply chains: Pharma 2020: PwC #merck #pharma

Posted On Dec 18 2017 by

#pharma supply # Pharma 2020: Supplying the future Which path will you take? Supply chain, the link between the laboratory and the marketplace, needs a thorough revision Most pharma have complex supply chains that are under-utilised, inefficient and ill-equipped to cope with the sort of products coming down the pipeline. This new report predicts that in order to meet the demands of a fast evolving marketplace and the shift from patient to outcome, the pharma supply chain will need to undergo a radical overhaul. Numerous forces are reshaping the environment in which the industry operates and dictating the need for …


Download vision to decision report: Pharma 2020: PwC #nutra #pharma #corp

Posted On Dec 3 2017 by

#pharmaceutical industry trends # Download the report In this report, we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter. The pharmaceutical industry is at a critical juncture. The tools to develop remarkable new medicines are materialising, demand for its products is increasing and the barriers to free trade are falling. But pharma also faces major economic and operational challenges, if it’s to capitalise on these opportunities and create more value for healthcare payers, providers and patients. Many of the conditions that will determine what happens in 2020 are already in place. …


Download vision to decision report: Pharma 2020: PwC #biotech #pharma #jobs

Posted On Nov 6 2017 by

#pharmaceutical industry trends # Download the report In this report, we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter. The pharmaceutical industry is at a critical juncture. The tools to develop remarkable new medicines are materialising, demand for its products is increasing and the barriers to free trade are falling. But pharma also faces major economic and operational challenges, if it’s to capitalise on these opportunities and create more value for healthcare payers, providers and patients. Many of the conditions that will determine what happens in 2020 are already in place. …


Opportunities and outlook facing pharmaceutical companies: Pharma 2020: PwC #cardiome #pharma

Posted On Oct 5 2017 by

#pharmaceutical industry growth # Market opportunities Collectively the mature markets generate 59% of the total revenues but they are becoming more difficult places where to prosper. They are demanding better outcomes as a precondition for paying for new medicines. Financial pressures have played a part in hardening healthcare payers’ policies. Crushing demographic and epidemiological factors have compounded these economic woes. Our report identifies four ways for pharma to offer more value without charging more or to prove that it can remove costs from another part of the healthcare system to make room for the higher prices it’s charging. Plugging leaks …


Opportunities and outlook facing pharmaceutical companies: Pharma 2020: PwC #hitech #pharma

Posted On Sep 7 2017 by

#pharmaceutical industry growth # Market opportunities Collectively the mature markets generate 59% of the total revenues but they are becoming more difficult places where to prosper. They are demanding better outcomes as a precondition for paying for new medicines. Financial pressures have played a part in hardening healthcare payers’ policies. Crushing demographic and epidemiological factors have compounded these economic woes. Our report identifies four ways for pharma to offer more value without charging more or to prove that it can remove costs from another part of the healthcare system to make room for the higher prices it’s charging. Plugging leaks …


Changes in pharma supply chains: Pharma 2020: PwC #contract #pharmaceutical #companies

Posted On Sep 6 2017 by

#pharma supply # Pharma 2020: Supplying the future Which path will you take? Supply chain, the link between the laboratory and the marketplace, needs a thorough revision Most pharma have complex supply chains that are under-utilised, inefficient and ill-equipped to cope with the sort of products coming down the pipeline. This new report predicts that in order to meet the demands of a fast evolving marketplace and the shift from patient to outcome, the pharma supply chain will need to undergo a radical overhaul. Numerous forces are reshaping the environment in which the industry operates and dictating the need for …


Download vision to decision report: Pharma 2020: PwC #pharmaceutical #manufacturing

Posted On Aug 17 2017 by

#pharmaceutical industry trends # Download the report In this report, we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter. The pharmaceutical industry is at a critical juncture. The tools to develop remarkable new medicines are materialising, demand for its products is increasing and the barriers to free trade are falling. But pharma also faces major economic and operational challenges, if it’s to capitalise on these opportunities and create more value for healthcare payers, providers and patients. Many of the conditions that will determine what happens in 2020 are already in place. …


Opportunities and outlook facing pharmaceutical companies: Pharma 2020: PwC #pharma #company #jobs

Posted On Aug 8 2017 by

#pharmaceutical industry growth # Market opportunities Collectively the mature markets generate 59% of the total revenues but they are becoming more difficult places where to prosper. They are demanding better outcomes as a precondition for paying for new medicines. Financial pressures have played a part in hardening healthcare payers’ policies. Crushing demographic and epidemiological factors have compounded these economic woes. Our report identifies four ways for pharma to offer more value without charging more or to prove that it can remove costs from another part of the healthcare system to make room for the higher prices it’s charging. Plugging leaks …